Bristol Myers Squibb reports successful trial for myeloma treatment
必治妥施貴寶報告骨髓瘤治療試驗取得成功
更新於: 2026年9月26日 上午02:50
Bristol Myers Squibb (BMS) is making significant strides in the fight against multiple myeloma, a complex blood cancer.
百時美施貴寶(Bristol Myers Squibb, BMS)在對抗多發性骨髓瘤(multiple myeloma)這項複雜的血癌上，正取得重大進展。
Central to this progress is ZENBEXUS™ (iberdomide), a novel CELMoD agent.
這項進展的核心是ZENBEXUS™(iberdomide)，這是一種新型的CELMoD製劑。
In the Phase 3 EXCALIBER-RRMM trial, patients using a regimen containing ZENBEXUS showed much better clinical outcomes compared to standard treatments.
在第3期EXCALIBER-RRMM試驗中，使用含ZENBEXUS治療方案的病患，其臨床成效較標準療法有顯著提升。
The U.S.
美國食品藥物管理局(FDA)近期給予該方案加速核准，對先前已接受過治療的患者而言，是一個重要的里程碑。
FDA recently granted accelerated approval for this regimen, marking a major milestone for patients who have already undergone prior therapy.
除了像ZENBEXUS和mezigdomide這類小分子藥物外，BMS也在推進其細胞療法管線。
Beyond small-molecule drugs like ZENBEXUS and mezigdomide, BMS is advancing its cell therapy pipeline.
第2期QUINTESSENTIAL試驗顯示，其研發中的CAR T細胞療法arlo-cel，在先前對其他療法產生抗藥性的患者中，達成了強勁的反應率。
The Phase 2 QUINTESSENTIAL trial revealed that its investigational CAR T-cell therapy, arlo-cel, achieved strong response rates in patients who were previously resistant to other treatments.
透過標靶GPRC5D，arlo-cel為那些已窮盡現有治療選項的患者提供了新的出路。
By targeting GPRC5D, arlo-cel offers a new path for those who have exhausted existing options.
隨著舊藥因學名藥競爭而導致營收下滑，這些創新療法對該公司的未來至關重要。
Through both CELMoD platforms and sophisticated CAR T technology, BMS is successfully refreshing its hematology portfolio to tackle treatment resistance.
